Researchers identified 11 promising experimental medicines for pre-eclampsia out of 83 candidates in early development, according to Gram Research analysis. Nearly half of these candidates are completely new drugs never tested before, though most target the same biological pathway. While these findings offer hope for better treatments in the future, pregnant women currently need to rely on existing medicines, and significant additional research and funding are required before these experimental candidates reach patients.
Pre-eclampsia is a dangerous pregnancy condition that affects millions of women worldwide, yet very few medicines exist to prevent or treat it. According to Gram Research analysis, scientists reviewed 83 experimental drug candidates in early development stages to identify which ones show the most promise. They discovered 11 high-potential medicines that could eventually help pregnant women, though most current treatments were originally designed for other diseases. The research highlights both exciting possibilities and the urgent need for more funding to develop safer, pregnancy-specific treatments.
Key Statistics
A 2026 analysis of 83 preclinical drug candidates for pre-eclampsia identified 11 high-potential medicines worthy of priority development, with 49.4% representing completely new chemical or biological entities never previously tested.
Among 83 experimental pre-eclampsia candidates analyzed in 2026, 32 candidates target the same biological pathway (sFlt-1 reduction), highlighting both a promising mechanism and a lack of diversity in the preclinical pipeline.
A 2026 research review found that 63 of 83 preclinical pre-eclampsia candidates were ranked as medium-potential and 9 as low-potential, indicating a significant pipeline behind the 11 high-potential medicines identified.
According to a 2026 analysis, 37 different biological targets were identified across the preclinical pre-eclampsia pipeline, suggesting researchers are exploring multiple mechanisms despite heavy concentration on a single pathway.
The Quick Take
- What they studied: Which experimental medicines being developed in laboratories show the best potential to prevent or treat pre-eclampsia, a serious pregnancy condition
- Who participated: Analysis of 83 experimental drug candidates identified from global research databases between 2000 and 2025; no human participants were involved in this review study
- Key finding: Researchers identified 11 high-potential drug candidates worthy of further development, with 49.4% being completely new medicines never tested before, though most target the same biological pathway
- What it means for you: Better treatments for pre-eclampsia may be coming, but it will take years of additional research and investment before these experimental medicines reach pregnant women; current treatments remain limited
The Research Details
Scientists created a systematic ranking system to evaluate 83 experimental medicines for pre-eclampsia that are currently in early laboratory stages of development. They didn’t test these medicines on people or animals themselves; instead, they reviewed existing research and development information about each candidate. Each medicine was scored across three main areas: the quality of laboratory evidence supporting it, how far along it is in development, and how practical it would be to actually use in pregnant women’s care.
The researchers assigned numerical scores to different factors—like whether the medicine is completely new versus modified from existing drugs, what biological target it attacks, and what mechanism it uses to work. These scores were added up to create an overall ranking for each candidate. This approach allowed them to identify which experimental medicines deserved priority attention for further development versus which ones faced bigger obstacles.
Understanding which early-stage medicines show the most promise helps scientists and funding organizations decide where to invest limited research dollars. By systematically evaluating the entire preclinical pipeline, researchers can avoid wasting resources on candidates unlikely to succeed and focus on those with the strongest foundation. This is especially important for pre-eclampsia because pregnant women currently have very few treatment options, and most existing medicines weren’t originally designed for pregnancy.
This study is a comprehensive analysis rather than an experiment, which means it reviews and organizes existing information rather than generating new data. The strength of the findings depends on the quality and completeness of information available about each candidate medicine. The researchers used a transparent, structured ranking system that could be verified and improved by other scientists. However, the analysis is limited by reliance on animal studies and laboratory models that don’t perfectly replicate how pre-eclampsia develops in pregnant women.
What the Results Show
Among 83 experimental medicines analyzed, researchers identified 11 as high-potential candidates deserving priority development. These 11 medicines represent the most promising options based on available evidence, developmental progress, and practical feasibility. An additional 63 candidates were ranked as medium-potential, meaning they show some promise but face more obstacles. Only 9 candidates were ranked as low-potential, suggesting they’re less likely to succeed.
Nearly half of all candidates (49.4%) are completely new chemical or biological entities—medicines that have never been tested before rather than modifications of existing drugs. This suggests the field is developing genuinely novel approaches to pre-eclampsia. However, the research revealed a significant limitation: 32 of the candidates target the same biological pathway, specifically reducing a protein called sFlt-1. While this convergence suggests scientists have identified an important mechanism, it also means the pipeline lacks diversity in approaches.
The analysis identified 37 different biological targets across all candidates, indicating that researchers are exploring multiple mechanisms to prevent or treat pre-eclampsia. This diversity is encouraging because it suggests backup options if one approach doesn’t work. The researchers also noted that current animal models used to test these medicines only partially capture the complexity of pre-eclampsia in real pregnant women, which is a significant limitation for predicting which candidates will actually work in humans.
This preclinical analysis complements previous research examining medicines already in clinical trials for pre-eclampsia. While earlier studies identified high-potential candidates in advanced development stages, this research reveals what’s coming behind them in the pipeline. The findings suggest that the preclinical pipeline is more robust than the clinical pipeline, with more candidates in early development than in human testing. However, the concentration on a single biological target (sFlt-1) reflects the current scientific understanding of pre-eclampsia mechanisms.
The study analyzed information about experimental medicines but didn’t conduct new laboratory or animal testing. The rankings depend on the quality and completeness of available information about each candidate. Animal models used to develop these medicines don’t perfectly replicate pre-eclampsia in pregnant women, so candidates that work well in animals may not work the same way in humans. The analysis also couldn’t predict which candidates will successfully move into human trials or ultimately reach patients. Additionally, the study only examined candidates in the preclinical stage, so it doesn’t account for medicines that may be in development but not yet documented in research databases.
The Bottom Line
Pregnant women and healthcare providers should continue using currently available treatments for pre-eclampsia, as these remain the only proven options. Funding organizations and research institutions should prioritize the 11 high-potential candidates identified in this analysis for further development. Scientists should work to develop better animal models and laboratory systems that more accurately reflect pre-eclampsia in pregnant women. The field needs increased investment to move promising candidates from laboratory research into human clinical trials. Confidence level: High for the need for continued investment; Moderate for specific candidate selection.
Pregnant women with pre-eclampsia or at high risk should care about this research because it identifies future treatment options. Healthcare providers managing pre-eclampsia should understand that better medicines are in development. Researchers and pharmaceutical companies should use these rankings to guide investment decisions. Public health organizations and governments should recognize the need for increased funding in this area. Women’s health advocates should use these findings to push for greater research investment in pregnancy-specific conditions.
The 11 high-potential candidates identified in this analysis are still in early laboratory stages. Realistically, it will take 5-10 years of additional preclinical research before the most promising candidates move into human clinical trials. Even after trials begin, it typically takes another 5-10 years to complete testing and gain regulatory approval. Therefore, new pre-eclampsia medicines from this pipeline are unlikely to reach pregnant women for at least 10-15 years. In the near term (next 2-3 years), expect to see increased research activity and publications about the top candidates.
Frequently Asked Questions
What new drugs are being developed for pre-eclampsia?
Researchers identified 11 high-potential experimental medicines in early development stages, with 49.4% being completely new drugs. Most target a protein called sFlt-1, though 37 different biological targets are being explored across the entire pipeline of 83 candidates.
When will new pre-eclampsia treatments be available?
The 11 promising candidates identified are still in early laboratory stages. Realistically, it will take 10-15 years before new medicines from this pipeline reach pregnant women, requiring additional preclinical research, clinical trials, and regulatory approval.
Why are there so few medicines for pre-eclampsia?
Pre-eclampsia is a pregnancy-specific condition, and most current treatments were originally designed for other diseases. Developing pregnancy-safe medicines requires extensive testing, and the condition’s complexity makes it challenging to create effective treatments. Limited research funding has also slowed progress.
How do scientists decide which experimental medicines to develop further?
Researchers use systematic ranking systems evaluating three factors: quality of laboratory evidence, developmental progress, and practical feasibility for pregnant women. The 11 high-potential candidates scored highest across these criteria and deserve priority funding and research attention.
Can animal testing predict if these medicines will work in pregnant women?
Animal models provide valuable information but only partially reflect pre-eclampsia’s complexity in humans. Medicines that work well in animals may not work the same way in pregnant women, which is why human clinical trials are essential before medicines reach patients.
Want to Apply This Research?
- Users at risk for pre-eclampsia could track blood pressure readings, protein levels in urine (if tested), and symptom changes like headaches or vision problems. This data helps identify early warning signs and supports conversations with healthcare providers about monitoring needs.
- Set reminders for regular prenatal appointments and blood pressure checks, which are critical for early detection of pre-eclampsia. Users can log symptoms and share trends with their healthcare team to ensure appropriate monitoring and early intervention with current available treatments.
- Establish a long-term tracking system for blood pressure and symptom patterns throughout pregnancy and postpartum periods. Users should document any new symptoms and share this information with their healthcare provider regularly, as early detection of pre-eclampsia is crucial for managing the condition with currently available treatments.
This article summarizes research about experimental medicines in early development stages. None of these candidates are currently approved for use in pregnant women. Pregnant women with pre-eclampsia or at risk should work with their healthcare provider to manage their condition using currently available, proven treatments. This research does not constitute medical advice. Always consult with your obstetrician or maternal health specialist before making any decisions about pregnancy care or treatment. The timeline for new medicines reaching patients is uncertain and may extend beyond current estimates.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.